Cerevel Therapeutics Faces Class Action Lawsuit Over Merger
The Gross Law Firm has issued an important notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV), highlighting critical updates regarding a class action lawsuit. Shareholders who acquired shares of ABBV during the specified period are encouraged to connect with the firm regarding their potential involvement.
Important Information for Shareholders
All individuals who bought shares during the class period described in the lawsuit are urged to reach out for details on becoming a lead plaintiff. It's essential to note that being a lead plaintiff isn’t necessary to recover any losses incurred.
Details of the Class Period
The lawsuit pertains to anyone who: (a) sold or otherwise disposed of publicly traded common stock of Cerevel from October 11, 2023, through August 1, 2024; (b) held shares as of January 8, 2024, the record date, and had the right to vote on the merger with AbbVie Inc.; (c) sold shares in line with Bain Capital's share acquisitions around October 16, 2023.
Allegations Against Cerevel Therapeutics
According to the complaint filed, Cerevel's secondary stock offering on October 16, 2023, allegedly lacked essential details regarding AbbVie's intention to acquire it at a significantly higher price than the offering price of $22.81 per share. This omission is said to have artificially lowered Cerevel's stock price until the merger announcement was made public.
Bain Capital's Position
Bain Capital Investors, LLC, Cerevel's dominant shareholder, reportedly purchased shares from this offering while having significant nonpublic information about AbbVie's interest in acquiring Cerevel. Following the announcement on December 6, 2023, that AbbVie planned to buy Cerevel for $45 per share, Bain Capital reaped considerable profits from their acquisitions during the depressed offering period.
Proxy Statement Concerns
Furthermore, concerns have been raised about Cerevel's Proxy statement dated January 18, 2024, which misled investors about the nature and timing of AbbVie's interest, further complicating the situation.
Upcoming Deadline for Registration
Shareholders are reminded that the deadline to participate in this class action is June 3, 2025. It’s important for affected shareholders to register promptly to ensure their voice is heard.
Steps for Affected Shareholders
By registering, shareholders who purchased ABBV shares during the designated time will be enrolled in a monitoring software that provides updates throughout the case's duration. To reiterate, there is no fee to register or participate as a shareholder in this matter.
Why Choose The Gross Law Firm?
The Gross Law Firm stands as a nationally recognized leader in class action lawsuits. Their commitment lies in safeguarding investor rights against deceit and fraudulent business practices. The firm's mission focuses on ensuring that companies adopt sound business ethics and are held accountable for misleading investors.
For those interested in learning more or seeking assistance, here is their contact information:
Contact Information
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The class action aims to hold Cerevel Therapeutics accountable for allegedly misleading shareholders about its merger with AbbVie.
Who can participate in the class action?
Anyone who purchased shares of ABBV during the specified class period can register and potentially participate in the lawsuit.
What allegations are made against Cerevel Therapeutics?
The allegations include failing to disclose material facts about the merger that could have influenced stock prices.
How will shareholders stay updated about the lawsuit?
Registered shareholders will receive status updates through portfolio monitoring software provided by The Gross Law Firm.
Is there a cost to participate in the class action?
No, there is no cost or obligation to participate as a shareholder in the lawsuit.
